All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

clomifene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives	700	911-45-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clomifene citrate clomifene clomiphene Clomiphene B clomiphene citrate clomid	A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. Note that ENCLOMIPHENE and ZUCLOMIPHENE are the (E) and (Z) isomers of Clomiphene respectively. Molecular weight: 405.97 Formula: C26H28ClNO CLOGP: 7.15 LIPINSKI: 1 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -5.99 ROTB: 9 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
9	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1.11 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	8 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.52 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	90 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Feb. 1, 1967	FDA	SANOFI AVENTIS US
March 11, 2022	PMDA	Fuji Pharma Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	254.23	32.67	110	1644	155437	63331831
Ovarian hyperstimulation syndrome	172.66	32.67	36	1718	3978	63483290
Abortion spontaneous	156.73	32.67	56	1698	47139	63440129
Heterotopic pregnancy	146.93	32.67	16	1738	6	63487262
Multiple pregnancy	93.92	32.67	12	1742	52	63487216
Ectopic pregnancy	93.02	32.67	20	1734	2547	63484721
Gestational diabetes	92.41	32.67	25	1729	8371	63478897
Adnexal torsion	91.38	32.67	15	1739	439	63486829
Retinopathy of prematurity	59.20	32.67	10	1744	349	63486919
Cleft lip	54.07	32.67	8	1746	116	63487152
Twin pregnancy	53.17	32.67	11	1743	1162	63486106
Foetal exposure during pregnancy	53.00	32.67	23	1731	31939	63455329
Pregnancy	49.87	32.67	23	1731	36813	63450455
Maternal exposure before pregnancy	49.30	32.67	15	1739	7588	63479680
Neonatal respiratory distress syndrome	48.57	32.67	12	1742	2806	63484462
Premature baby	48.20	32.67	19	1735	20716	63466552
Abortion threatened	48.14	32.67	9	1745	563	63486705
Maternal exposure during pregnancy	45.63	32.67	42	1712	220020	63267248
Ruptured ectopic pregnancy	43.32	32.67	8	1746	468	63486800
Abortion	39.87	32.67	10	1744	2486	63484782
Caesarean section	37.46	32.67	15	1739	17017	63470251

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Foetal exposure during pregnancy	62.07	46.07	23	524	38078	34918306
Testicular atrophy	52.99	46.07	9	538	583	34955801
Muscle mass	52.61	46.07	8	539	256	34956128

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	181.04	30.82	35	1616	3536	79739201
Heterotopic pregnancy	151.55	30.82	16	1635	6	79742731
Exposure during pregnancy	121.15	30.82	53	1598	101079	79641658
Abortion spontaneous	107.66	30.82	35	1616	29472	79713265
Ectopic pregnancy	106.51	30.82	20	1631	1723	79741014
Gestational diabetes	101.49	30.82	24	1627	6269	79736468
Multiple pregnancy	91.94	30.82	11	1640	35	79742702
Adnexal torsion	90.74	30.82	14	1637	369	79742368
Twin pregnancy	65.73	30.82	12	1639	884	79741853
Abortion threatened	53.41	30.82	9	1642	416	79742321
Testicular atrophy	47.62	30.82	8	1643	363	79742374
Maternal exposure before pregnancy	46.78	30.82	12	1639	4361	79738376
Ruptured ectopic pregnancy	46.42	30.82	8	1643	423	79742314
Caesarean section	46.18	30.82	15	1636	12520	79730217
Muscle mass	45.83	30.82	8	1643	456	79742281
Maternal exposure during pregnancy	41.55	30.82	29	1622	136509	79606228
Benign hydatidiform mole	34.27	30.82	5	1646	89	79742648
Pregnancy	31.78	30.82	14	1637	26837	79715900

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G03GB02	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM GONADOTROPINS AND OTHER OVULATION STIMULANTS Ovulation stimulants, synthetic
FDA MoA	N0000000168	Selective Estrogen Receptor Modulators
CHEBI has role	CHEBI:50837	oestrogen antagonist
CHEBI has role	CHEBI:50751	anti-estrogenic drug
MeSH PA	D004965	Estrogen Antagonists
MeSH PA	D020847	Estrogen Receptor Modulators
MeSH PA	D005300	Fertility Agents, Female
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D012102	Reproductive Control Agents
MeSH PA	D020845	Selective Estrogen Receptor Modulators
FDA EPC	N0000175826	Estrogen Agonist/Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Female infertility	indication	6738008
Ovulation induction	indication	61285001
Controlled ovarian stimulation	indication	732970000
Induction of spermatogenesis	indication
Male infertility	off-label use	2904007	DOID:12336
Oligozoospermia	off-label use	88311004
Ovarian Function Studies	off-label use
Corpus Luteum Insufficiency Syndrome	off-label use
Diagonstic Test for Hypothalamic Pituitary Gonadal Axis	off-label use
Severe adrenal insufficiency	contraindication	24867002
Depressive disorder	contraindication	35489007
Hypothyroidism	contraindication	40930008	DOID:1459
Thrombophlebitis	contraindication	64156001	DOID:3875
Intermenstrual bleeding - irregular	contraindication	64996003
Polycystic ovaries	contraindication	69878008
Cyst of ovary	contraindication	79883001
Thyrotoxicosis	contraindication	90739004	DOID:7997
Neoplasm of pituitary gland	contraindication	127024001	DOID:1785
Endometriosis	contraindication	129103003
Ovarian hyperstimulation syndrome	contraindication	129635004	DOID:5425
Disease of liver	contraindication	235856003	DOID:409
Endometrial carcinoma	contraindication	254878006	DOID:2871
Pregnancy, function	contraindication	289908002
Lesion of brain	contraindication	301766008
Thromboembolic disorder	contraindication	371039008
Visual impairment	contraindication	397540003
Visual Disturbance of Seeing Spots	contraindication
Scotomata	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.9	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN	MODULATOR	Ki	8.89		DRUG MATRIX	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.46		DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	8.10		CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.75		WOMBAT-PK
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Enzyme	Q15125	EBP_HUMAN		Ki	9		CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.47		DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.07		DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.03		DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.06		DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.18		DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.71		CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.14		DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.35		DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	5.19		WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.41		DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.89		DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.36		DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.64		DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	5.90		DRUG MATRIX
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	5.37		DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.67		DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	6.21		DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	5		DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.52		DRUG MATRIX
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	5.98		DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.60		DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	5.78		DRUG MATRIX
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.82		DRUG MATRIX
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN		IC50	6.46		DRUG MATRIX
Androgen receptor	Transcription factor		ANDR_RAT		IC50	4.87		CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.60		DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	7.52		DRUG MATRIX
C-8 sterol isomerase	Enzyme		ERG2_YEAST		Ki	6.80		CHEMBL

External reference:

ID	Source
4018616	VUID
N0000179535	NUI
D00962	KEGG_DRUG
50-41-9	SECONDARY_CAS_RN
142431	RXNORM
4018616	VANDF
4019686	VANDF
C0009008	UMLSCUI
CHEBI:3752	CHEBI
53Q	PDB_CHEM_ID
CHEMBL2355051	ChEMBL_ID
CHEMBL3185958	ChEMBL_ID
DB00882	DRUGBANK_ID
4159	IUPHAR_LIGAND_ID
1548955	PUBCHEM_CID
356	MMSL
362	MMSL
4475	MMSL
d00569	MMSL
002101	NDDF
004781	NDDF
30466001	SNOMEDCT_US
387166005	SNOMEDCT_US
387346007	SNOMEDCT_US
D002996	MESH_DESCRIPTOR_UI
1309	INN_ID
1HRS458QU2	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clomid	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0885	TABLET	50 mg	ORAL	ANDA	17 sections
Clomid	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0885	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-114	TABLET	50 mg	ORAL	ANDA	18 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	49884-701	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	49884-701	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0677	TABLET	50 mg	ORAL	NDA authorized generic	22 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0678	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0678	TABLET	50 mg	ORAL	ANDA	17 sections
CLOMID	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6500	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3059	TABLET	50 mg	ORAL	ANDA	17 sections
CLOMIPHENE CITRATE	HUMAN PRESCRIPTION DRUG LABEL	1	61919-375	TABLET	50 mg	ORAL	ANDA	10 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2165	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2165	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-5302	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-5302	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-5302	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-9276	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	68071-2638	TABLET	50 mg	ORAL	ANDA	17 sections
Clomiphene Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	68071-4676	TABLET	50 mg	ORAL	ANDA	17 sections